Treatment of T. cruzi infected human platelet concentrates with aminomethyltrimethyl psoralen (AMT) and ultravioleta (UV-A) light: preliminary results

Abstracts

The present measures adopted to prevent transfusion-associated Chagas' disease include screening of blood donors. and/or the inactivation of T. cruzi in collected blood using gentian violet (GV) as a trypanocidal agent. In this study, we investigated the efficacy of the combined use of AMT and UV-A in inactirating T. cruzi in infected human platelet cuncentrates. Human platelet concentrates were infected with T. cruzi (2x10/ml) of the Y strain transfered to PL 269 (Fenwal Laboratories) containers and treated with GV (250řg,/ml). and ascorbic acid (1 mg/ml); GV. ascorbic acid and UV-A; GV and UV-A; AMT (40/tG/ml) and ascorbic acid; AMT, ascorbic acid and UV-A; AMT and UV-A; UV-A alone; and untreated (control). All UV-A treated platelet concentrates were exposed to UV-A doses of 24, 92, 184, 276, 368 and 644 kj/m². and the microscopical research of active T. cruzi was performed, using the microhematocrit technique, 1, 6 and 24 hours after each treatment. A high number of active forms of T. cruzi was observed in all condictions, except when GV was used as the trypanocidal agent, providing evidence of the failure of AMT and UV-A in inactivating T cruzi in infected human platelet concentrates.

Transfusion-associated Chagas' disease; Phtodynamic treatment; UV-A and Chagas' disease; Chemoprophylaxis; Blood transfusion

As medidas adotadas atualmente para prevenir a doença de Chagas transfusional incluem a seleção dos doadores de sangue e/ou a inativação do T. cruzi no sangue coletado através do uso da violeta de genciana (VG) como agente tripanosomicida. Neste estudo, nós investigamos a eficácia do uso combinado do AMTe da UV-A para a neutralização do T. cruzi em concentrados de plaquetas humanas infectados. Os concentrados de plaquetas infectados com cepa Y de T. cruzi (2x10/ml) foram transferidos para recipientes PL. 269 (Fenwal Laboratories) e tratados com VG (250/ml) e ácido ascórbico (1mg/ml) VG. ácido ascórbico e UV-A; GV e UV-A; AMT (40 G/ml) e ácido ascórbico; AMT, ácido ascórbico e UV-A; AMT e UV-A; somente UV-A; e não tratado (controle). Todos os concentrados de plaquetas foram expostos a doses de 24, 92, 184, 276, 368 e 644 kJ/m² de UV-A, e a pesquisa microscópica do T. cruzi foi realizada pela técnica do microbematócrito, 1, 6 e 24 horas após cada tratamento. Grande número de formas ativas de T. cruzi foi observado em todos os experimentos, exceto quando foi usada a VG como o agente tripanosomicida, evidenciando a ineficácia do AMT e da luz ultravioleta em inativar o T. cruzi nos concentrados de plaquetas humanas infectados.

Doença de Chagas transfusional; Quimioprofilaxia; Tratamento fotodinâmico; Luz ultravioleta e doença de Chagas; Transfusão de sangue

NOTA PRÉVIA

Treatment of T. cruzi infected human platelet concentrates with aminomethyltrimethyl psoralen (AMT) and ultravioleta (UV-A) light: preliminary results

Hélio Moraes-Souza; José Orlando Bordin; Leslie Bardossy; Morris A. Blajchman

Department of Pathology, McMaster University and the Canadian Red Cross Society, Hamilton, Ontario, Canada; Faculdade de Medicina do Triângulo Mineiro/Fundação Hemominas, Uberaba, MG, Brazil; and Universidade Federal de São Paulo/Escola Paulista de Medicina

^{Endereço para correspondência}

SUMMARY

The present measures adopted to prevent transfusion-associated Chagas' disease include screening of blood donors. and/or the inactivation of T. cruzi in collected blood using gentian violet (GV) as a trypanocidal agent. In this study, we investigated the efficacy of the combined use of AMT and UV-A in inactirating T. cruzi in infected human platelet cuncentrates. Human platelet concentrates were infected with T. cruzi (2x10/ml) of the Y strain transfered to PL 269 (Fenwal Laboratories) containers and treated with GV (250řg,^/ml). and ascorbic acid (1 mg/ml); GV. ascorbic acid and UV-A; GV and UV-A; AMT (40/tG/ml) and ascorbic acid; AMT, ascorbic acid and UV-A; AMT and UV-A; UV-A alone; and untreated (control). All UV-A treated platelet concentrates were exposed to UV-A doses of 24, 92, 184, 276, 368 and 644 kj/m². and the microscopical research of active T. cruzi was performed, using the microhematocrit technique, 1, 6 and 24 hours after each treatment. A high number of active forms of T. cruzi was observed in all condictions, except when GV was used as the trypanocidal agent, providing evidence of the failure of AMT and UV-A in inactivating T cruzi in infected human platelet concentrates.

Key-words: Transfusion-associated Chagas' disease. Phtodynamic treatment. UV-A and Chagas' disease. Chemoprophylaxis. Blood transfusion.

RESUMO

As medidas adotadas atualmente para prevenir a doença de Chagas transfusional incluem a seleção dos doadores de sangue e/ou a inativação do T. cruzi no sangue coletado através do uso da violeta de genciana (VG) como agente tripanosomicida. Neste estudo, nós investigamos a eficácia do uso combinado do AMTe da UV-A para a neutralização do T. cruzi em concentrados de plaquetas humanas infectados. Os concentrados de plaquetas infectados com cepa Y de T. cruzi (2x10/ml) foram transferidos para recipientes PL. 269 (Fenwal Laboratories) e tratados com VG (250/ml) e ácido ascórbico (1mg/ml) VG. ácido ascórbico e UV-A; GV e UV-A; AMT (40 G/ml) e ácido ascórbico; AMT, ácido ascórbico e UV-A; AMT e UV-A; somente UV-A; e não tratado (controle). Todos os concentrados de plaquetas foram expostos a doses de 24, 92, 184, 276, 368 e 644 kJ/m² de UV-A, e a pesquisa microscópica do T. cruzi foi realizada pela técnica do microbematócrito, 1, 6 e 24 horas após cada tratamento. Grande número de formas ativas de T. cruzi foi observado em todos os experimentos, exceto quando foi usada a VG como o agente tripanosomicida, evidenciando a ineficácia do AMT e da luz ultravioleta em inativar o T. cruzi nos concentrados de plaquetas humanas infectados.

Palavras-chaves: Doença de Chagas transfusional. Quimioprofilaxia. Tratamento fotodinâmico. Luz ultravioleta e doença de Chagas. Transfusão de sangue.

Texto completo disponível apenas em PDF.

Full text available only in PDF format.

Recebido para publicação em 27/12/95.

• 1. Appleman MD, Shulman IA, Saxena S, Kirchhoff LV. Use of a questionnaire to identify potential blood donors at risk for infection with Trypanosoma cruzi. Transfusion 33:61-64,1993.
• 2. Camargo ME. Serological diagnosis.An appraisal of Chagas' disease serodiagnosis. In: Wendel S, Brener Z, Camargo ME, Rassi A (eds) Chagas disease (American trypanosomiasis): its impact on transfusion and clinicai medicine. São Paulo, p. 165-178,1992.
• 3. Gottlieb P, Ben-Hur E, Lustigman S, Margolis- Nunno H, Horowitz B. Parasite inactivation in red blood cells and platelet concentrates by photodynamic treatment.Transfusion 34(suppl): 435, 1994
• 4. Kirchhoff LV. American trypanosomiasis (Chagas' disease). A tropical disease now in the United States. The New England Journal of Medicine 329:639-644,1993.
• 5. Margolis-Nuno H,Williams B, Rywkin S, Geacintov N, Horowitz B. Virus sterilization in platelet concentrates with psoralen and ultraviolet A light in the presence of quenchers. Transfusion 32:541-547,1992.
• 6. Ramirez LE, Lages-Silva E, Pianetti GM, Rabelo RMC, Bordin JO, Moraes-Souza H. Prevention of transfusion-associated Chagas' disease by sterilization of T. cruzi-infected blood with gentian violet, ascorbic acid and light. Transfusion 35: 226-230,1995.
• 7. Schmunis GA. Tiypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and nonendemic countries. Transfusion 31:547-557,1991.
• 8. Wagner S, Bardossy L, Moroff G, Doddy RY, Blajchman MA. Assessment of the hemostatic effectiveness of human platelet treated with aminomethyltrimethyl psoralen and UV-A light using a rabbit ear bleeding time technique. Blood 82:3489-3492,1993.
• 9. Woo PTK. Evaluation of the hematocrit centrifuge and other techniques for the field diagnosis of human trypanosomiasis and filariasis. ActaTropica 28:298-303,1971.

Endereço para correspondência:

Prof. Hélio Moraes-Souza.

Hemocentro Regional de Uberaba, R. Getúlio Guaritá 250,

38025-440 Uberaba, MG.

Publication Dates

• Publication in this collection
  09 Apr 2013
• Date of issue
  Feb 1996

History

• Received
  27 Dec 1995
• Accepted
  27 Dec 1995